Kura Oncology, Inc. (KURA)
Develops cancer drugs targeting menin protein to stop tumor growth.
$9.31-0.08%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+54.7%
The outlook
KURA trades at $9.31, sitting below both its 50- and 200-day moving averages after a modest decline today. Analyst consensus is Strong Buy with an average price target about 235% above the current price. The stock sits roughly midway in its 52-week range, with technical positioning lagging recent averages despite bullish analyst sentiment.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 12 analysts
Price trendBelow its 50- & 200-day averages
52-week range55% of the way from its 52-week low to high
Price targetAvg target +235% vs current price
Analyst price target
~12-month · 12 analysts$31.17average target+234.8% vs now
Now $9.31
Low $15.00High $76.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$826.5M
52-wk high
$12.49
52-wk low
$5.45
50-day avg
$10.21
200-day avg
$9.66
Trailing P/E
—